ALK and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) recommends that all patients diagnosed with nonsquamous NSCLC or NSCLC not otherwise specified be tested for ALK rearrangements so patients with ALK-positive tumors can receive targeted treatment (NCCN, 2016).